Uplizna (Inebilizumab-cdon Injection) Uses
Uplizna (Inebilizumab-cdon) is a CD19-directed cytolytic antibody used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Dosage: Inebilizumab-cdon is administered as an intravenous infusion. The recommended dosage is: Initial dose: 300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion. Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months.
Side Effects: The most commonly reported uplizna side effects include:
- Urinary tract infection
Warnings and Precautions:
Monitor patients with lurbinectedin injection for infusion reactions during and for at least one hour after the completion of the infusion. Patients should be assessed for the tuberculosis risk factors and tested for latent infection prior to initiating inebilizumab-cdon. Monitor the levels of quantitative serum immunoglobulins while on therapy with lurbinectedin 100 mg, mainly in patients with opportunistic or recurrent infections, and until B-cell repletion after discontinuation of therapy. Patients are advised that the uplizna uses may cause reactivation of hepatitis B infection and that monitoring will be needed in case they are at risk. Administration of live-attenuated or live vaccines is not recommended while receiving uplizna dose until B-cell recovery. Patients who are pregnant or plan to become pregnant while taking uplizna injection should inform their health specialist.